| Recruiting | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 Melanoma, Metastatic Melanoma, Advanced Solid Tumor | — | 2025-12-12 |
| Recruiting | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in I Metastatic Uveal Melanoma | Phase 2 / Phase 3 | 2024-12-17 |
| Recruiting | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC Hepatocellular Carcinoma, Biliary Tract Cancer | Phase 2 | 2024-08-01 |
| Recruiting | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [ Advanced Melanoma | Phase 3 | 2024-07-11 |
| Withdrawn | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recur Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | 2024-01-30 |
| Terminated | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC Refractory Metastatic Colorectal Cancer, pMMR, MSS | Phase 2 | 2023-06-29 |
| Active Not Recruiting | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours Advanced Solid Tumor | Phase 1 | 2020-12-29 |
| Recruiting | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2020-05-15 |
| Active Not Recruiting | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Cancer | Phase 1 | 2019-10-17 |
| Active Not Recruiting | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma | Phase 2 | 2019-10-08 |
| Active Not Recruiting | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC) | Phase 2 | 2017-09-20 |
| No Longer Available | An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma Advanced Melanoma | — | — |